HEMATOLOGY

Amer Zeidan, MBBS, discusses imetelstat and the IMerge/MDS3001 study of the agent in patients with lower-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.

Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.

Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.

An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.

Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.

A myelofibrosis specialist discusses his approach to monitoring treatment response in patients with myelofibrosis.

Dr Oh provides clinical insights on sequencing therapies for patients with myelofibrosis and discusses the sequential use of JAK inhibitors.

An expert on myelofibrosis discusses how to determine whether a patient is experiencing ruxolitinib failure or disease progression and provides insights on when to intervene or change therapy.

Stephen T. Oh, MD, PhD, presents the case of a 63-year-old man previously diagnosed and treated with primary myelofibrosis.

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

In closing the discussion, Dr Mascarenhas shares clinical pearls for community oncologists treating patients with myelofibrosis.

John Mascarenhas, MD, looks to the future of myelofibrosis treatment, noting present challenges and treatment strategies in development that may address those unmet needs.

Focusing on the safety profiles of JAK2 inhibitors, a myelofibrosis specialist discusses the adverse events encountered with pacritinib, ruxolitinib, and momelotinib.

John Mascarenhas, MD, reviews JAK2 inhibitor options for patients with myelofibrosis, including pacritinib, ruxolitinib, and momelotinib.

An expert on myelofibrosis discusses clinical studies investigating pacritinib, including data from the latest survival analysis of the PERSIST-2 clinical trial.

A hematologist-oncologist gives an overview of the treatment of myelofibrosis by defining the disease and highlighting biological pathways, therapeutic options, and factors that drive treatment selection.

John O. Mascarenhas, MD, presents the case of a 62-year-old man with myelofibrosis and provides clinical insights on treatment decisions.

Musa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.

Stephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.

Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.